PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

RESTART tICrH: Randomized Test of 1- vs 4-Week DOAC Resumption

direct oral anticoagulantsDOACapixabanrivaroxabanedoxabandabigatranwarfarintraumatic intracranial haemorrhageatrial fibrillationvenous thromboembolismanticoagulation restartRCT protocolneuropharmacologygeriatric trauma Neurology / Neuropharmacology

Background Information

When should DOACs restart after brain bleeding? This trial aims to find out.

Restarting direct oral anticoagulants (DOACs) after traumatic intracranial haemorrhage (tICH) involves balancing bleeding and thrombotic risks with no current consensus on timing. The study randomizes patients to restart DOACs either 1 week or 4 weeks post-tICH, assessing outcomes like haemorrhagic or thrombotic events within 12 weeks. This trial aims to inform clinical practice by providing evidence on the optimal timing for restarting DOACs after tICH, directly impacting patient care protocols. Timely DOAC re-initiation after tICH can optimize patient outcomes, reducing bleeding and thrombotic risks.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Edlmann E, Kannan S, Wright L, Hardwick B, Brown M, Gornall M, McLoughlin T, Haunton V, Pijeira Perez Y, Hughes DA, Vine N, Grantham H, Milling TJ, Lane DA, Lip GYH, Jenkinson MD, McMahon CJ

Citation: Edlmann E, Kannan S, Wright L, et al. Timing to restart direct oral anticoagulants after traumatic intracranial haemorrhage (RESTART tICrH): study protocol for a randomised controlled multicentre trial. BMJ open. 2026;16(9):e121224. doi:10.1136/bmjopen-2026-121224

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.